Can a rheumatoid arthritis drug save COVID-19 patients from lung failure?
NCT ID NCT04363853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug tocilizumab can help people with severe or critical COVID-19 who have serious lung problems (ARDS). About 200 adults will receive one or two doses and be followed for 30 days. The goal is to see if the drug improves survival and recovery. There is no placebo group because of the high risk of death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute of Mexico
Mexico City, Mexico City, 14080, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield lungs from COVID-19's worst damage?
- French ICU study reveals COVID-19 patient outcomes
- Massive study reveals COVID-19 risks for autoimmune patients
- COVID infection study in hospital staff withdrawn before start
- Can early COVID-19 drugs keep high-risk patients out of the hospital?
- COVID-19 ICU patients may face higher superbug risk